Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27559170 | 0.85 | NOTUM (0.46) | NOTUML3MBTL1MAPTNPC1RAB9A | |
| SCHEMBL10558185 | 0.85 | NOTUM (0.44) | NOTUMMAPTNPC1RAB9ARXRA | |
| SCHEMBL1607911 | 0.83 | NOTUM (0.64) | NOTUMMAPTCNR2AMPD2ALDH1A1 | |
| SCHEMBL6605105 | 0.83 | NOTUM (0.64) | NOTUMMAPTCNR2AMPD2ALDH1A1 | |
| SCHEMBL15677111 | 0.82 | NOTUM (0.43) | NOTUML3MBTL1MAPTNPC1RAB9A | |
| SCHEMBL5461555 | 0.81 | NOTUM (0.62) | NOTUMMAPTCNR2AMPD2ALDH1A1 | |
| SCHEMBL3025336 | 0.81 | NOTUM (0.62) | NOTUMCNR2AMPD2 | |
| SCHEMBL6527995 | 0.81 | NOTUM (0.62) | NOTUMMAPTCNR2AMPD2ALDH1A1 | |
| SCHEMBL10560223 | 0.81 | NOTUM (0.57) | NOTUML3MBTL1MAPTNPC1RAB9A | |
| SCHEMBL2204666 | 0.79 | NOTUM (0.59) | NOTUMMAPTHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| EP-1216239-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023374-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | NOTUM 4293/4885L3MBTL1 4844/4885MAPT 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.